Trial Profile

Phase 2 Trial of Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 01 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cobimetinib (Primary)
Indications Chronic myelomonocytic leukaemia
Focus Therapeutic Use
Acronyms CONCERTO

Most Recent Events

08 Mar 2023 Planned End Date changed from 15 Aug 2025 to 15 Aug 2026.
08 Mar 2023 Planned primary completion date changed from 15 Aug 2023 to 15 Aug 2025.
13 Dec 2022 Results (n=9) assessing efficacy of cobimetinib monotherapy in CMML pts preselected for RAS/MAPK activating mutations presented at the 64th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com